Browsing Tag
SIX Swiss Exchange
6 posts
Inside Galderma’s €500m bond deal and what it reveals about the dermatology market’s financial momentum
Galderma raises €500M via a five-year eurobond to refinance IPO debt and strengthen its balance sheet. Discover what this means for GALD investors.
Galderma share buyback: CHF 232m repurchase follows full exit by EQT, ADIA, and Auba Investment
Galderma repurchases CHF 232M in shares as EQT exits. Discover what the buyback and ownership shift mean for the dermatology company and investors.
What Galderma Group AG’s new CFO appointment reveals about its next phase as a global dermatology company
Galderma Group AG appoints a new CFO as it enters its post-IPO phase. Find out what the leadership change signals for investors and strategy.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
89bio stock soars 85% as Roche seals $3.5bn takeover—What’s behind the surge and what’s next?
Roche is buying 89bio for up to $3.5B to add Phase 3 MASH drug pegozafermin. Find out what the CVR means and how investors should read the deal today.
Novartis to acquire Regulus Therapeutics in $1.7bn deal to advance farabursen for ADPKD treatment
Novartis to acquire Regulus Therapeutics for $1.7 billion, gaining next-gen kidney drug farabursen for ADPKD. Read the market reaction and deal insights.